Abstract
Refractory anemia with excess blasts in transformation (RAEB-T) is a subgroup of myelodysplastic syndrome (MDS) in which the bone marrow blast count ranges from 20% to 30%. The recently proposed World Health Organization Classification of Hematologic Malignancies eliminated this category from MDS by lowering the blast count cutoff for acute myeloid leukemia (AML) from 30% to 20%. However, MDS is distinguished from AML by a significant increase in apoptosis. To investigate the difference in apoptosis between RAEB-T, AML, and other categories of MDS, we prospectively analyzed fresh bone marrow samples using the Annexin V and mitochondrial potential assays. There was a significantly higher level of apoptosis in RAEB-T than in AML according to both assays, while no significant differences between RAEB-T and other categories of MDS were noted. The data suggest that RAEB-T is more likely to be an advanced stage of MDS and biologically different from AML.
Original language | English (US) |
---|---|
Pages (from-to) | 2249-2252 |
Number of pages | 4 |
Journal | Leukemia |
Volume | 16 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2002 |
Keywords
- Acute myelogenous leukemia
- Apoptosis
- Myelodysplastic syndrome
- Refractory anemia with excess blasts in transformation
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research